Clinical Trial Update: SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas [Phase 2]

View source ↗

Summary

Phase II trial of pembrolizumab (MK-3475) in advanced soft tissue and bone sarcomas completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Sarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Sarcoma Alliance for Research through Collaboration | Conditions: Soft Tissue Sarcoma, Bone Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-29